The high prevalence of chronic diseases such as diabetes, cardiovascular disease, respiratory diseases and others is expected to drive the active pharmaceutical ingredients (API) market. The burden of chronic disease is affecting the population in different of the globe, such as Vietnam, China, Mongolia etc., at a rapid rate all over the world and worsening the health and quality of the people life. Chronic diseases involving diabetes, heart disease, respiratory disease, arthritis, Parkinson’s disorder, multiple sclerosis, and alzehimers among others, can lead to long-term disability and also worsens the health of people in Vietnam.
Access Full Report @ https://www.databridgemarketresearch.com/de/reports/vietnam-active-pharmaceutical-ingredient-api-market
In Vietnam, the incidence of diabetes has been increasing at an alarming rate, with it doubling in the past 10 years. The number of pre-diabetics has also increased by three times as many as there are diabetics.
Thus, this signifies that with the high prevalence of chronic disorders, the demand for the development and innovation of active pharmaceutical ingredients (API) is increasing, hence, leading to the growth of the Vietnam active pharmaceutical ingredients (API) market over the forecast period.
Data Bridge Market Research analyses that the Vietnam Active Pharmaceutical Ingredients (API) Market is expected to grow at a CAGR of 6.8% from 2023 to 2030 and expected to reach USD 1,793.37 million by 2030, increased prevalence of chronic diseases and the rising aging population is expected to drive the growth of Vietnam active pharmaceutical ingredients (API) market
Key Findings of the Study
The increase in the aging population
The geriatric populations bring a greater chance of health issues and are more prone to several kinds of diseases such as respiratory, cardiovascular, diabetes and many others. As per several conducted studies, geriatric populations aged 80 years and above have worse quality of life which enhances the overall morbidity and mortality rate.
Geriatric populations have weakened immune system that enhances the chances of getting disease affected. With the increasing geriatric population and rising prevalence of chronic diseases, the demand for effective treatment is also increasing. Moreover, with the increasing aging population, the pressure on healthcare providers is also increasing, which is ultimately pushing toward the demand for treatment.
The elderly population brings a greater chance of health issue, the rapid growth in the geriatric population are more prone to various types of health disorders such as osteoporosis, type 2 diabetes, hypertension and Alzheimer's disease. These health disorders are increasing exponentially as per the age of the population.
For Instance,
- Dementia affects around 500,000 Vietnamese aged above 60, accounting for 5% of the population in the age group, while more young people have it too. 1 in 3 people dies from dementia
As the aging population will increase in the forecast period, different health issues related with aging will increase in the coming period. Therefore, the demand for treatment will increase, which will drive the growth of the Vietnam active pharmaceutical ingredients (API) market
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, and Pricing in USD
|
|
Segments Covered
|
By Therapeutic Class (Antibiotic, Cardiovascular, Lipid Lowering Drugs, Infectious Disease, Anesthetic, NSAIDs, Analgesic, Antiviral, Dermatology, Oncology, Endocrinology, Urology, Gastroenterology, Ophthalmology, Hormonal Agents, Muscle Relaxant, Parkinson, Psoriasis, Epileptic, Immunology, Hematology, Antineoplastic, Immunosuppressive Agents, and Others), Type (Innovative Active Pharmaceutical Ingredient and Generic Active Pharmaceutical Ingredient), Type of Manufacturer (Captive Manufacturers and Merchant Manufacturer), Synthesis (Chemical Synthetic and Biotech), Type of Drug (Prescription Drugs and Over-the-Counter), Application (Clinical, Research), Potency (Traditional Potency Active Pharmaceutical Ingredient and High Potency Active Pharmaceutical Ingredient), Molecule (Small Molecule and Large Molecule), End User (Pharmaceutical Industries, Biotechnology Industries, Research and Academic Institutes, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others)
|
|
Countries Covered
|
Vietnam
|
|
Market Players Covered
|
Pfizer Inc.(U.S.), MEKOPHAR(Vietnam), AstraZeneca (U.K), Divi's Laboratories Limited(India), Sanofi(France), Dr. Reddy’s Laboratories Ltd.(India), Aurobindo Pharma (India), Sun Pharmaceutical Industries Ltd. (India), BASF SE(Germany), Lupin (India), and Boehringer Ingelheim International GmbH. (Germany) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios, such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis
Vietnam active pharmaceutical ingredients (API) market is categorized into ten notable segments, which are based on the therapeutic class, type, type of manufacturer, synthesis, potency, type of drug, molecule, application, end user, and distribution channel.
- On the basis of therapeutic class, Vietnam active pharmaceutical ingredients (API) market is segmented into antibiotic, cardiovascular, lipid-lowering drugs, infectious disease, anesthetic, NSAIDs, analgesic, antiviral, dermatology, oncology, endocrinology, urology, gastroenterology, ophthalmology, hormonal agents, muscle relaxant, Parkinson, psoriasis, epileptic, immunology, hematology, antineoplastic, immunosuppressive agents, others.
In 2023, the antibiotic segment is anticipated to dominate the Vietnam active pharmaceutical ingredients (API) market.
In 2023, the antibiotic segment of this market will dominate the Vietnam active pharmaceutical ingredients (API) market owing to the increasing prevalence of chronic disorder in the region. The antibiotic segment is expected reach the highest CAGR of 10.7% in the forecast period of 2023-2030.
- On the basis of type, Vietnam active pharmaceutical ingredients (API) market is segmented into innovative active pharmaceutical ingredients and generic active pharmaceutical ingredients. In 2023, the innovative active pharmaceutical ingredients segment is expected to dominate the active pharmaceutical ingredients (API) market because of the high cost of innovative APIs in comparison to generic APIs and rising FDA approval for the new molecular entities
- . On the basis of type of manufacturer, Vietnam active pharmaceutical ingredients (API) market is segmented into captive manufacturers and merchant manufacturers. In 2023, the captive manufacturer segment is expected to dominate the active pharmaceutical ingredients (API) market due to huge investments by major market players to generate high-end manufacturing facilities and easy availability of raw materials
- On the basis of synthesis, Vietnam active pharmaceutical ingredients (API) market is segmented into chemical synthetic and biotech. Chemical synthesis is further sub-segmented into saxagliptin, enoxaparin sodium, rufinamide, tamoxifen, artemisinin, losartan potassium, naproxen, ibuprofen acetaminophen, sodium chloride and others. The biotech segment is further sub-segmented into monoclonal antibodies, cytokines, hormones & growth factors, blood factors, recombinant vaccines, and therapeutic enzymes. In 2023, Chemical synthetic is expected to dominate the active pharmaceutical ingredients (API) market because of easy protocol for the synthesis of molecules, less stringent regulatory guidelines and in the coming year, many synthetic molecules will go off patent
- On the basis of potency, Vietnam active pharmaceutical ingredients (API) market is segmented into traditional potency active pharmaceutical ingredients and high potency active pharmaceutical ingredients. In 2023, traditional potency Active Pharmaceutical Ingredient is expected to dominate the Active Pharmaceutical Ingredients (API) market because of their less toxicity and less hazardous nature
- On the basis of type of drug, the Vietnam active pharmaceutical ingredients (API) market is segmented into prescription drugs and over-the-counter drugs. In 2023, the prescription drugs segment is dominating the active pharmaceutical ingredients (API) market because high cost of the drugs, which will increase the APIs and manufacturing cost of the APIs
- On the basis of molecule, Vietnam active pharmaceutical ingredients (API) market is segmented into small molecule, and large molecule. In 2023, the small molecule segment is expected to dominate the active pharmaceutical ingredients (API) market due to their small size and high penetration power
- On the basis of application, Vietnam active pharmaceutical ingredients (API) market is segmented into clinical and research. In 2023, the clinical segment is expected to dominate the active pharmaceutical ingredients (API) market because a rising number of diseases, which require a continuous supply of APIs and raw materials. Moreover, rising clinical trials are also attributed to dominate the market
- On the basis of end user, Vietnam active pharmaceutical ingredients (API) market is segmented into pharmaceutical industries, biotechnology industries, research and academic institutes and other pharmaceutical industries is further segmented into large, medium, and small. Biotechnology is further segmented into large, medium, and small. In 2023, the pharmaceutical industries segment is expected to dominate the active pharmaceutical ingredients (API) market because due to rising research and development on novel molecules due to their beneficial effects
- On the basis of distribution channel, Vietnam active pharmaceutical ingredients (API) market is segmented into direct tenders, retail sales and others.
In 2023, the pharmaceutical industries segment is projected to hold the largest share of end user segment in the Vietnam active pharmaceutical ingredients (API) market.
In 2023, the pharmaceutical industries segment holds maximum market share due to rising research and development on novel molecules due to their beneficial effects.
The pharmaceutical industries segment is growing with a CAGR of 7.3% in the forecast period of 2023 to 2030.
Major Players
Data Bridge Market Research recognizes the following companies as the major Vietnam active pharmaceutical ingredients (API) market players in Vietnam active pharmaceutical ingredients (API) are Pfizer Inc.(U.S.), MEKOPHAR(Vietnam), AstraZeneca(U.K), Divi's Laboratories Limited(India), Sanofi(France), Dr. Reddy’s Laboratories Ltd.(India), Aurobindo Pharma (India), Sun Pharmaceutical Industries Ltd. (India), BASF SE(Germany), Lupin (India), and Boehringer Ingelheim International GmbH.(Germany) among others.
Market Developments
- In January 2023, U.S. FDA accepted the supplemental new drug application for Jardiance for adults with chronic kidney disease
- In June 2022, Pfizer announced the submission of a new drug application to the U.S. FDA for paxlovid. This helps the organization developing its product category
- In October 2021, Boehringer Ingelheim International Gmbh. inaugurated its state-of-the-art biopharmaceutical production facility, Large Scale Cell Culture (LSCC), in Vienna, Austria, with an investment volume of more than 700 million EUR, the single largest investment in the company's history
- In April 2020, Dr. Reddy’s Laboratories Ltd. has received the EIR, which is an establishment inspection report from the U.S. healthcare regulator. The company has received the EIR for an active pharmaceutical manufacturing unit established in Nalgonda. EIR is received by the USFDA when the inspection done by USDFDA is satisfactory and the facilities available in the manufacturing plant is up to the mark. This EIR approval helped the company to boost up their manufacturing facilities which will increase their production of products at the end
- In May, Pfizer Inc 2019. expanded its business by opening of new manufacturing facility in Andover, Massachusetts. The company has adopted this initiative in order to boost up the manufacturing of pharmaceutical products with an aim to improve patients’ treatment options. This initiative allowed the company to build up a strong partnership with the research and development manufacturing teams
Regional Analysis
Geographically, the countries covered in the Vietnam active pharmaceutical ingredients (API) market report are Vietnam.
As per Data Bridge Market Research analysis:
Anti-biotic segment is the dominant region in Vietnam active pharmaceutical ingredients (API) market during the forecast period 2023 - 2030
In 2023, the anti-biotic segment is expected to dominate the Vietnam active pharmaceutical ingredients (API) market with a 12.79% market share. This is due to its increasing aging population and prevalence of chronic disease.
Anti-biotic is estimated to be the fastest growing region in Vietnam active pharmaceutical ingredients (API) market the forecast period 2023 - 2030
Anti-biotic is expected to grow during the forecast period due to rising research and development on novel molecules due to their beneficial effects.
For more detailed information about the Vietnam active pharmaceutical ingredients (API) market, click here – https://www.databridgemarketresearch.com/de/reports/vietnam-active-pharmaceutical-ingredient-api-market
